34 results about "Monoclonal antibody 14G2A" patented technology

The invention discloses a humanized monoclonal antibody targeting to human CD19 antigen. The humanized monoclonal antibody is applied to construction and preparation of chimeric antigen receptor T cells; and subsequent in-vitro experiments verify the tumor treatment effect of the chimeric antigen receptor T cells. A chimeric antigen receptor targeting to the human CD19 antigen is composed of a leader peptide, a single-chain antibody targeting to the human CD19 antigen, a hinge area for connection with ScFv, a transmembrane domain and an immune receptor tyrosine activation motif; a lentiviral expression vector is constructed from the chimeric antigen receptor and then used for infection of immune cells, so the chimeric antigen receptor targeting to the human CD19 antigen can be expressed in the immune cells; and tumors expressing the CD19 antigen are killed by recognizing the CD19 antigen on the surfaces of tumor cells, so the purpose of tumor treatment is achieved. The invention provides a novel tool for targeting therapy of tumors.

Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line is produced by cell fusion of a parental cell and a myeloma cell line and has the same characteristics as the cell line whose strain designation is CmA40 and deposition number is ATCC (To be Provided). The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus.

The present invention relates to methods for inhibiting tumor growth, increasing survival of a subject having a tumor and inducing protection against tumor recurrence in a mammal. The methods comprise administering a humanized monoclonal antibody comprising CDR regions derived from the murine monoclonal antibody designated mBAT-1, in combination with at least one chemotherapeutic agent.

The invention belongs to the technical field of medical bioengineering, and particularly relates to a hybridoma cell with the number of CCTCCNO:C2014167 and a monoclonal antibody LACZ4H3 secreted by the hybridoma cell and resisting prostate minute protein, and applications. The hybridoma cell and the monoclonal antibody secreted by the hybridoma cell can be prepared by taking prostate minute escape protein, separated from a patient body suffering from chronic prostatitis and prostate cancer, as an antigen. The hybridoma cell can stably generate the prostate-resisting minute protein monoclonal antibody, the cell chromosome is stable, the valence of the antibody is high, and the monoclonal antibody can be entirely applied into the research applied in the prostate minute protein. The monoclonal antibody resisting prostate minute protein can be applied into preparation of a reagent for detecting the prostate minute protein.

The invention discloses monoclonal antibody BTV16-2B4 resistant to bluetongue virus serum 16 type VP2 protein, B-cell epitope identified by the monoclonal antibody BTV16-2B4, and applications of the monoclonal antibody BTV16-2B4, and belongs to the field of bluetongue prevention. The invention also relates to a hybridoma cell strain which is capable of secreting the monoclonal antibody BTV16-2B4, and monoclonal antibody secreted by the hybridoma cell strain. It is shown by indirect immunofluorescence assay that the specific reaction is observed between the monoclonal antibody and BTV16, and no cross reaction is observed between the monoclonal antibody and other serum types of bluetongue virus, Ibaraki virus or Chuzan disease virus. Further, BTV16-VP2 protein B-cell epitope polypeptide which can be identified by the monoclonal antibody is determined via cutting expression antigen short peptide and peptide scanning technology. The monoclonal antibody, and the BTV16-VP2 protein B-cell epitope polypeptide identified by the monoclonal antibody can be used for preparation of BTV16 specific differential diagnosis reagents, and foundation is provided for development of BTV epitope labeled vaccines.

The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such a mesenchymal precursor cells (MPCs).

The invention provides a hybridoma cell strain 2D5 capable of secreting an anti-cattle-interferon inducing protein-10(IP-10) monoclonal antibody and a secreted monoclonal antibody MAb 2D5. The monoclonal antibody MAb 2D5 has the advantages of high titer, excellent specificity and strong affinity with natural cattle IP-10 antigen. A blocking ELISA detection kit, a Western-Blot detection kit, an indirect immunofluorescence (IFA) detection kit and a flow cytometry (FCM) detection kit which are established on the basis of the monoclonal antibody MAb 2D5 have higher sensitivity and specificity and can be applied to the detection for recombination expression cattle IP-10, the detection for in vitro tissues and the non-diagnosis purpose research, such as epitope identification.

The invention discloses a method for screening and identifying tumor/testis antigens based on monoclonal antibodies with spermatogenic cell specificities. Spermatogenic cells of human bodies are used as immune antigens, monoclonal antibodies are prepared by the aid of the lymphocyte hybridoma technology, the monoclonal antibodies with spermatogenic cell specificities are screened by the aid of immunohistochemistry, and then the expression distribution law of antigens identified on the screened monoclonal antibodies on tumor tissues and other normal tissues is researched on a protein level. The monoclonal antibodies are selected for the expression law of the tumor/testis antigens by the aid of immunohistochemical staining on the basis to be used as candidate antibodies for identifying the tumor/testis antigens, and new tumor/testis antigen molecules recognized by the monoclonal antibodies can be identified by the aid of proteomics technologies such as immunoprecipitation-mass spectrum analysis and the like.

The invention discloses a monoclonal antibody against an extracellular domain of a goose CD3 epsilon chain and an application of the monoclonal antibody in detection of goose CD3<+> T lymphocytes. Amplification is performed by adopting goose thymus cDNA as a template to obtain a goose CD3 epsilon gene, according to the characteristics of a GoCD3 epsilon extracellular domain gene, a pair of specific primers are designed, amplification is performed to obtain the goose CD3 epsilon extracellular domain gene (CD3 epsilon ex) and the CD3 epsilon ex is expressed by virtue of escherichia coli; the recombinant plasmid containing the CD3 epsilon ex is adopted as an immunogen to immunize BALB/c mice, and the recombinant protein rGoCD3 epsilon is used for booster immunization to obtain a hybridoma cell strain (3C11) capable of stably secreting the monoclonal antibody against the extracellular domain of the goose CD3 epsilon chain. The monoclonal antibody can react with the purified recombinant protein rGoCD3 epsilon and can have a specific reaction with separated goose peripheral blood lymphocytes. Therefore, a novel and effective technical means is provided for detecting the goose CD3<+> T lymphocytes.

The invention discloses a hybridoma cell strain 2C1 capable of secreting CAV-2 monoclonal antibodies, the monoclonal antibodies secreted by the cell strain and application. The preservation number of the hybridoma cell strain 2C1 is CGMCC No. 10878. An indirect immunofluorescence result shows that the monoclonal antibodies secreted by the hybridoma cell strain 2C1 can specifically recognize CAV-2 viruses and do not react with MDCK (madin-darby canine kidney) cells. A result of a superposition experiment of the hybridoma cell strain 2C1 and two monoclonal antibodies secreted by another hybridoma cell strain shows that the two monoclonal antibodies are used for different antigenic epitopes of the CAV-2 viruses. The monoclonal antibody prepared by the invention can react with CAV-2 well and can be used for identifying a clinic isolated strain. The 2C1 monoclonal antibody and the 7D7 monoclonal antibody which are prepared by the invention are used for recognizing two different antigen determinants of the CAV-2, so that the monoclonal antibodies can be used for detecting preparation of CAV-2 pathogenic colloidal gold and establishment of a sandwiched ELISA (enzyme-linked immuno sorbent assay) method.

The invention discloses monoclonal antibodies resistant to a PLAG (platelet-aggregation-stimulating) domain of human PDPN (Podoplanin) and an application of the monoclonal antibodies. The monoclonal antibodies are secreted by hybridoma cell lines with preservation numbers of CCTCC NO: C201613 and CCTCC NO: C2015185 respectively, are named as SZ-163 and SZ-168 and are both IgG1 subclass antibodies; the monoclonal antibodies are specifically bound with reductive PDPN, are bound with an NCI-H226 cell Lysis solution to generate a binding zone when the molecular weight is 36 kDa, and are bound with a recombinant human PDPN-Fc to generate a binding zone when the molecular weight is 67 kDa. One anti-PDPN monoclonal antibody can block platelet activating aggregation induced through binding of tumor cells and platelets, and the other anti-PDPN monoclonal antibody can be bound with the first functional inhibiting antibody at different epitopes of PDPN. The antibodies can be used for preparing an anti-tumor-metastasis drug or establishing a double-antibody sandwich method for measuring the content of soluble PDPN in human plasma.

The invention provides a hybridoma cell line for secreting a monoclonal antibody against chromogranin A and application of the hybridoma cell line and also provides an application method of secreted monoclonal antibody capable of specifically recognizing human chromogranin A for immunological diagnosis on multiple kinds of tumors. CgA protein is a soluble acidic protein with highest content in human adrenal medulla, has the molecular weight being 48kD and extensively exists in neurons as well as neuroendocrine cells and tumor cells thereof. CgA protein expression is related to neuroendocrine tumors, and is used for marking the neuroendocrine tumors, thus being used for diagnosing the neuroendocrine tumors. An antigen for preparing the antibody is a recombinant protein which is expressed by escherichia coli and has immunogenicity activity, and the finally obtained antibody belongs to an IgG2b subtype. Discovered by immunohistochemistry assay on multiple kinds of tumor tissues, the antibody can well identify tumor occurrence and can be used for immunological diagnosis of the tumors.

The invention relates to two strains of hybridoma cells capable of secreting mouse anti CysC monoclonal antibodies; the two strains of hybridoma cells of the mouse anti CysC monoclonal antibodies arecultured by an in vitro serum-free culture method, and the monoclonal antibodies are prepared. The invention also relates to a use of the monoclonal antibodies for kits for detection of CysC in humanserum, plasma or whole blood. The monoclonal antibodies have the advantages of high sensitivity, strong specificity, good stability and high purity.